BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report published on Tuesday, TipRanks reports. They currently have a $30.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also commented on BCRX. Royal Bank of Canada reduced their price target on shares of BioCryst Pharmaceuticals from $16.00 to $14.00 and set a sector perform rating for the company in a report on Thursday, November 4th. Oppenheimer assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, December 9th. They set an outperform rating and a $16.00 price objective for the company. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, November 8th. Barclays cut their price target on shares of BioCryst Pharmaceuticals from $21.00 to $17.00 and set an overweight rating on the stock in a research note on Thursday, November 4th. Finally, JMP Securities reaffirmed a buy rating and issued a $23.00 price objective on shares of BioCryst Pharmaceuticals in a report on Thursday, September 16th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of Buy and an average price target of $19.82.

BCRX stock opened at $15.48 on Tuesday. BioCryst Pharmaceuticals has a 12 month low of $8.37 and a 12 month high of $18.48. The company has a 50-day moving average price of $12.87 and a 200 day moving average price of $14.51.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Tuesday, November 2nd. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The business had revenue of $40.99 million for the quarter, compared to the consensus estimate of $37.75 million. During the same period last year, the business posted ($0.26) earnings per share. As a group, research analysts expect that BioCryst Pharmaceuticals will post -1.26 earnings per share for the current year.

In related news, Director George B. Abercrombie sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 15th. The shares were sold at an average price of $12.27, for a total transaction of $61,350.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jon P. Stonehouse sold 184,000 shares of the stock in a transaction dated Tuesday, January 11th. The stock was sold at an average price of $15.04, for a total transaction of $2,767,360.00. The disclosure for this sale can be found here. Insiders sold 219,100 shares of company stock valued at $3,195,930 over the last quarter. Company insiders own 4.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Two Sigma Advisers LP boosted its stake in shares of BioCryst Pharmaceuticals by 171.3% in the third quarter. Two Sigma Advisers LP now owns 1,921,012 shares of the biotechnology company’s stock valued at $27,605,000 after purchasing an additional 1,212,900 shares during the period. Fisher Asset Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 49.4% in the third quarter. Fisher Asset Management LLC now owns 3,005,622 shares of the biotechnology company’s stock valued at $43,191,000 after purchasing an additional 994,391 shares during the period. Renaissance Technologies LLC boosted its stake in shares of BioCryst Pharmaceuticals by 1,430.3% in the second quarter. Renaissance Technologies LLC now owns 1,032,480 shares of the biotechnology company’s stock valued at $16,324,000 after purchasing an additional 965,010 shares during the period. Federated Hermes Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 2,898.2% in the second quarter. Federated Hermes Inc. now owns 746,971 shares of the biotechnology company’s stock valued at $11,810,000 after purchasing an additional 722,057 shares during the period. Finally, PFM Health Sciences LP purchased a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $11,208,000. 57.20% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever.

Featured Article: Trading Penny Stocks

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.